Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system-Reference-Cited by-同舟云学术

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system

Published:2019-02-14 Issue:4 Volume:109 Page:426-439
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Kizaki Masahiro, ,Takahashi Naoto^ORCID,Iriyama Noriyoshi,Okamoto Shinichiro,Ono Takaaki,Usui Noriko,Inokuchi Koiti,Nakaseko Chiaki,Kurokawa Mineo,Sumi Masahiko,Nakamura Fumihiko,Kawaguchi Tatsuya,Suzuki Ritsuro,Yamamoto Kazuhito,Ohnishi Kazunori,Matsumura Itaru,Naoe Tomoki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-019-02613-1/fulltext.html

Reference20 articles.

1. Kizaki M, Okamoto S, Tauchi T, Tanaka H, Tanimoto M, Inokuchi K, et al. Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH. Int J Hematol. 2008;88:409–17.

2. Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585–90.

3. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

4. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

5. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia;International Journal of Hematology;2024-05-15

3. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group;International Journal of Hematology;2024-04-08

4. 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China;Frontiers in Medicine;2023-11-16

5. Dasatinib-Triggered Severe Hypocalcemia in a Patient with Chronic Kidney Disease and Osteoporosis;Cureus;2023-11-09